Abstract:BackgroundHeparin-induced thrombocytopenia (HIT) is screened for using an assay that detects antibodies to platelet factor 4 (PF4). While the presence of PF4 antibodies is a strong indicator for HIT, some PF4 antibodies are not functionally pathogenic. The gold standard test for HIT diagnosis is the serotonin release assay (SRA), which more directly measures the presence of pathogenic platelet activation. Therefore, the SRA facilitates proper anticoagulation management of PF4-positive or -indeterminate patients, yet a significant number of these patients in our institution do not receive follow-up SRA testing. Conversely, a positive SRA is very unlikely when the PF4 is negative, so an SRA may not be clinically useful. This prompted us to investigate the SRA ordering practices across different regions of our healthcare system with the intention of further optimizing SRA utilization.MethodsPF4 and SRA data was collected over a 10 month period, January 2023 - October 2023. SRA ordering frequency, stratified by qualitative PF4 results based on a 0.4 OD threshold, from two similarly sized medical centers within the Sanford Health system was compared. The probability of SRA-positivity in relation to PF4 OD value was determined by logistic regression. Receiver operator characteristic (ROC) analysis was subsequently utilized to select a PF4 OD threshold for SRA reflex.ResultsSystem-wide, 14.4% (36/250) of PF4-negative patients and 40.5% (17/42) of PF4-positive patients received SRA testing. Within our health system, the Department of Pharmacy in hospital "A" maintains close oversight of anticoagulation therapy through an anticoagulation stewardship workgroup, while hospital "B" has not implemented a similar strategy. Stratifying by hospital demonstrated significant differences in local ordering practice. Hospital "B" performed SRA testing on 24.4% (32/131) of PF4-negative patients vs. 3.4% (4/119) for hospital "A. SRA testing frequency for PF4-positive patients was similar at 42.96% and 35.7%, for hospitals "B" and "A", respectively. Logistic regression suggested a low probability (≤10%) for SRA-positivity when PF4 values are <0.8 OD. The ROC AUC was 0.862 (95% CI: 0.778-0.946) with an estimated sensitivity of 83% (95% CI: 77.8-90.8%) and specificity of 22.6% (95% CI: 13.5-35.5%) at a reflex decision threshold of 0.82 OD. Despite the ROC estimates, in this dataset the 0.82 OD threshold would have produced 100% sensitivity and 75% specificity. The discrepancy between the estimated and observed sensitivity/specificity is likely a factor of our small dataset used for ROC analysis (n = 53); optimization efforts would thus likely benefit from ongoing threshold performance monitoring.ConclusionsAn anticoagulation stewardship strategy was moderately successful in optimizing SRA ordering on suspected HIT patients, specifically in minimizing SRA testing on PF4-negative patients. The PF4-positive OD value generally corresponds to the probability of SRA-positivity, i.e., strongly positive-PF4s are more likely to also be SRA-positive. Thus, further optimization can be achieved by implementation of an SRA reflex threshold. This is especially important for low OD-positive PF4 cases in which the likelihood for HIT diagnosis via positive-SRA is reduced.

Anti-PF4 ELISA-Negative, SRA-Positive Heparin-Induced Thrombocytopenia

False-Negative Platelet Factor 4 Antibodies and Serotonin Release Assay and the Utility of Repeat Testing in the Diagnosis of Heparin-Induced Thrombocytopenia and Thrombosis

Serotonin-release assay-negative heparin-induced thrombocytopenia

Serotonin-release assay-positive but platelet factor 4-dependent enzyme-immunoassay negative: HIT or not HIT?

Absolute Immature Platelet Counts in the Setting of Suspected Heparin-Induced Thrombocytopenia May Predict Anti-Pf4-heparin Immunoassay Testing Results

Unique features of vaccine-induced immune thrombotic thrombocytopenia; a new anti-platelet factor 4 antibody-mediated disorder

Clinical and economic implications of false-positive heparin-induced thrombocytopenia immunoassays: utility of the 4T score

Variable serotonin release assay pattern and specificity of PF4-specific antibodies in HIT, and clinical relevance

A-160 Optimization of Serotonin Release Assay Utilization for Heparin-Induced Thrombocytopenia Diagnosis

Laboratory testing for platelet factor 4 antibodies: differential utility for diagnosis/exclusion of heparin induced thrombocytopenia versus suspected vaccine induced thrombotic thrombocytopenia

A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia

Laboratory Testing for Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: A Narrative Review

Diagnosing heparin-induced thrombocytopenia: The need for accuracy and speed

A comparative study of platelet factor 4-enhanced platelet activation assays for the diagnosis of heparin-induced thrombocytopenia

Evaluating Diagnostic Algorithms for Heparin-Induced Thrombocytopenia using Two Combined Automated Rapid Immunoassays

High sensitivity and specificity of a new functional flow cytometry assay for clinically significant heparin-induced thrombocytopenia antibodies

Evaluating heparin-induced thrombocytopenia: the old and the new

Use of a whole-cell ELISA to detect additional antibodies in setting of suspected heparin-induced thrombocytopenia

Laboratory tests for identification or exclusion of heparin induced thrombocytopenia: HIT or miss?

Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG

Rapid and accurate Bayesian diagnosis of heparin-induced thrombocytopenia